June 5th Essure Problems Email Update to FDA Officials
This post is a reprint of an email update the Essure Problems Facebook admin team sent to the FDA. Reprinted with permission.
This post is a reprint of an email update the Essure Problems Facebook admin team sent to the FDA. Reprinted with permission.
Last week, a jury in federal court in East St. Louis, Illinois sided with a ten-year old boy who was born with spina bifida. The boy’s lawsuit, filed by his mother, alleged that AbbVie’s popular bipolar medication, Depakote, was the cause of his birth defect.
It’s been a great week for women’s health in Europe. Just the other day, I had the pleasure of writing a piece on Bayer pulling Essure from the market in Finland. Today, thanks to a number of readers, I get the joy of writing a similar piece. It has been confirmed by Bayer that the company is withdrawing from the UK market as of September 1, 2017.
It’s your worst nightmare. After years of carefully managing your finances, some unscrupulous individual steals your identity and begins opening accounts, taking loans, and committing you to deal with the aftermath. All your hard work, gone in the time it took a thief to fill out some applications (most of which are now done online).
I was recently contacted by a fellow writer in reference to the letter you’re about to read. Due to my coverage of the Essure issue, he thought that our readers would like to see Dr. Novoa’s Essure letter to fellow doctors. It’s with my colleague’s permission that I share their post and Dr. Novoa’s letter.
It’s with great sadness that I write this piece. On May 24, 2017, the world lost an amazing advocate for women’s health. Dr. Amy Reed died at her home in Yardley, Pennsylvania at age 44, after a long battle with leiomyosarcoma of the uterus.
I’m not going to take a picture of myself attempting to jump up and down; no one but my chiropractor wants to see that! However, the sentiment is very much present as I get to write these incredible words: Essure is soon to be history in Finland!
Last week, the first bellwether trial over Xarelto, a “new generation” blood thinner jointly developed by Bayer and Johnson & Johnson, concluded. The jury found in favor of the Big Pharma defendants on Wednesday, after less than three hours of deliberation. Bellwether trials are a means for parties and attorneys to test their arguments and
This week’s Feel Good Friday is brought to you by corporate greed and those of us who despise it. Unlike the usual Feel Good Friday article, this post doesn’t highlight an individual lawyer, a law firm, or a legal organization. This one is more of a public service piece suggested to me by a very
Friday, April 28 was not a good day for Johnson & Johnson and its Ethicon division. The most recent suit over the giant corporation’s TVT-Secur transvaginal mesh concluded and the jury found in favor of plaintiff, Margaret “Peggy” Engleman. The eight-woman, four-man jury awarded Ms. Engleman $20 million, the third multimillion-dollar verdict against J&J in